cancers
Article
Over-Detection of Melanoma-Suspect Lesions by a CE-Certified
Smartphone App: Performance in Comparison to
Dermatologists, 2D and 3D Convolutional Neural Networks in
a Prospective Data Set of 1204 Pigmented Skin Lesions
Involving Patients’ Perception
AnnaSophieJahn1,†,AlexanderAndreasNavarini1,†,SaraElisaCerminara1,LisaKostner1,
StephanieMarieHuber1,MichaelKunz1,Julia-TatjanaMaul2,3 ,ReinhardDummer2 ,SerainaSommer1,
AnjaDominiqueNeuner1,MitchellPaulLevesque2,3 ,PhilFangCheng2 andLaraValeskaMaul1,*
1 DepartmentofDermatology,UniversityHospitalofBasel,4031Basel,Switzerland
2 DepartmentofDermatology,UniversityHospitalofZurich,8091Zurich,Switzerland
3 FacultyofMedicine,UniversityofZurich,8006Zurich,Switzerland
* Correspondence:laravaleska.maul@usb.ch;Tel.:+41-61-265-40-80
† Theseauthorscontributedequallytothiswork.
Simple Summary: Early detection and resection of cutaneous melanoma are crucial for a good
Citation:Jahn,A.S.;Navarini,A.A.; prognosis.However,visualdistinctionofearlymelanomasfrombenignneviremainschallenging.
Cerminara,S.E.;Kostner,L.;Huber, Newartificialintelligence-basedapproachesforriskstratificationofpigmentedskinlesionsprovide
S.M.;Kunz,M.;Maul,J.-T.;Dummer, screening methods for laypersons with increasing use of smartphone applications (apps). Our
R.;Sommer,S.;Neuner,A.D.;etal. studyaimstoprospectivelyinvestigatethediagnosticaccuracyofaCE-certifiedsmartphoneapp,
Over-DetectionofMelanoma-Suspect SkinVision®,inmelanomarecognition.Basedonclassificationintothreedifferentriskscores,theapp
LesionsbyaCE-Certified
providesarecommendationtoconsultadermatologist.Inaddition,bothpatients’anddermatologists’
SmartphoneApp:Performancein
perspectives towards AI-based mobile health apps were evaluated. We observed that the app
ComparisontoDermatologists,2D
classifiedasignificantlyhighernumberoflesionsashigh-riskthandermatologists,whichwould
and3DConvolutionalNeural
haveledtoaclinicallyharmfulnumberofunnecessaryexcisions. Thediagnosticperformanceof
NetworksinaProspectiveDataSetof
theappindichotomousclassificationof1204pigmentedskinlesions(riskclassificationfornevus
1204PigmentedSkinLesions
vs. melanoma)remainedbelowadvertisedrateswithlowsensitivity(41.3–83.3%)andspecificity
InvolvingPatients’Perception.
Cancers2022,14,3829. https:// (60.0–82.9%).Theconfidenceintheappwaslowamongbothpatientsanddermatologists,andno
doi.org/10.3390/cancers14153829 patientfavoredanassessmentbytheappalone.Althoughsmartphoneappsareapotentialmedium
forincreasingawarenessofmelanomascreeninginthelaypopulation,theyshouldbeevaluatedfor
AcademicEditor:ÁngelesJuarranz
certificationwithprospectivereal-worldevidence.
Received:28June2022
Accepted:5August2022 Abstract:Theexponentialincreaseinalgorithm-basedmobilehealth(mHealth)applications(apps)
Published:7August2022 formelanomascreeningisareactiontoagrowingmarket.However,theperformanceofavailable
appsremainstobeinvestigated.Inthisprospectivestudy,weinvestigatedthediagnosticaccuracyof
Publisher’sNote:MDPIstaysneutral
withregardtojurisdictionalclaimsin aclass1CE-certifiedsmartphoneappinmelanomariskstratificationanditspatientanddermatolo-
publishedmapsandinstitutionalaffil- gistsatisfaction.Pigmentedskinlesions≥3mmandanysuspicioussmallerlesionswereassessedby
iations. thesmartphoneappSkinVision®(SkinVision®B.V.,Amsterdam,theNetherlands,App-Version6.8.1),
2DFotoFinderATBM®master(FotoFinderATBM®SystemsGmbH,BadBirnbach,Germany,Ver-
sion3.3.1.0),3DVectra®WB360(CanfieldScientific,Parsippany,NJ,USA,Version4.7.1)totalbody
photography(TBP)devices,anddermatologists. Thehigh-riskscoreofthesmartphoneappwas
Copyright: © 2022 by the authors.
comparedwiththetwogoldstandards:histologicaldiagnosis,orifnotavailable,thecombinationof
Licensee MDPI, Basel, Switzerland.
dermatologists’,2Dand3Driskassessments.Atotalof1204lesionsamong114patients(meanage
This article is an open access article
59years;51%females(55patientsathigh-riskfordevelopingamelanoma,59melanomapatients))
distributed under the terms and
wereincluded.Thesmartphoneapp’ssensitivity,specificity,andareaunderthereceiveroperating
conditionsoftheCreativeCommons
Attribution(CCBY)license(https:// characteristics(AUROC)variedbetween41.3–83.3%,60.0–82.9%,and0.62–0.72%accordingtotwo
creativecommons.org/licenses/by/ study-definedreferencestandards.Additionally,allpatientsanddermatologistscompletedanewly
4.0/). createdquestionnaireforpreferenceandtrustofscreeningtype.Thesmartphoneappwasratedas
Cancers2022,14,3829.https://doi.org/10.3390/cancers14153829 https://www.mdpi.com/journal/cancers
Cancers2022,14,3829 2of21
trustworthyby36%(20/55)ofpatientsathigh-riskformelanoma,49%(29/59)ofmelanomapatients,
and8.8%(10/114)ofdermatologists.Mostofthepatientsratedthe2DTBPimaging(93%(51/55)
resp.88%(52/59))andthe3DTBPimaging(91%(50/55)resp.90%(53/59))astrustworthy.Askin
cancerscreeningbycombinationofdermatologistandsmartphoneappwasfavoredbyonly1.8%
(1/55)resp. 3.4%(2/59)ofthepatients;nopatientpreferredanassessmentbyasmartphoneapp
alone.Thediagnosticaccuracyinclinicalpracticewasnotasreliableaspreviouslyadvertisedandthe
satisfactionwithsmartphoneappsformelanomariskstratificationwasscarce.MHealthappsmight
beapotentialmediumtoincreaseawarenessformelanomascreeninginthelaypopulation,but
healthcareprofessionalsandusersshouldbealertedtothepotentialharmofover-detectionandpoor
performance.Inconclusion,wesuggestfurtherrobustevidence-basedevaluationbeforeincluding
market-approvedappsinself-examinationforpublichealthbenefits.
Keywords: smartphone; mobile health application; melanoma; early detection; over-detection;
diagnosticaccuracy
1. Introduction
Cutaneousmelanomaisoneofthemostaggressivecancersinhumansandthusre-
mainsamajorclinicalchallenge[1].TheincidenceofmelanomainWesternpopulationshas
increasedrapidlyoverrecentdecades[2]. Despiteasignificantimprovementinprevention,
diagnosis,andtreatment,cutaneousmelanomaisstillassociatedwithahighmortalityand
morbidityrate[3–5]. Missingawarenessaboutskincancerpreventionandthemedical
needforbettertechniquestodistinguishnevifromearlymelanomasplayarelevantrole.
Earlydetectionandresectionofmelanomaarecrucialforimprovingpatientoutcomes[6,7].
Hence,theriseofartificialintelligence(AI)hasledtothehopeofnovelpatient-autonomous
melanomadiagnosis. Computer-aideddiagnostictoolshavealsobeendevelopedtoenable
earlydetectionofmelanomabylaypersonsinthepublic.
Throughdigitalizationandtheresultingwidespreadaccesstosmartphones,mostadults
intheworldownasmartphoneanduseapplications(apps).While92%oftheadultpopulation
intheU.S.ownedamobilephonein2015[8], upto97%hadamobilephonein2021[9].
Thereby,theuseofmobilehealth(mHealth)appshasrecentlyrisenconsiderablytoprovide
independenthealthcaretimeandlocation[10]. Between2014–2017,235newappsinthe
fieldofdermatologywereregisteredrepresentingagrowthof80.8%[11],whilemelanoma-
related apps increased by 55.8% [12]. Aside from the main functionality as a source of
informationorawarenessaboutmelanoma,prevention,andskinself-surveillancestrategies,
theappsincreasinglyprovidediagnosticandmonitoringcapabilitiesforpigmentedskin
lesions[13,14].
Appsusingmachinelearningalgorithmstoprovideriskstratificationhaveopened
newopportunitiesforthedetectionofmelanomabylaypersons,astheyofferimmediate
supportintheriskclassificationofpigmentedskinlesionsandwhethertheyrequirefurther
medicaladvice[15]. Currently,onlytheSkinVision® andTeleSkinskinScanappsconstitute
CE(ConformitéEuropéenne)certifiedmedicalproductsinEurope[15]. Furthermore,only
onesmartphoneapp,theDermaCompareapp(EmeraldMedicalApplications,Israel),has
been approved by the United States Food and Drug Administration (FDA) so far [16].
However,thissmartphoneappisconsideredaCEclass1medicaldevice(self-certified)
andisnotapprovedforclassifyingskinlesionsdirectly.
ThesmartphoneappSkinVision®isaCEclass1(self-certified)certifiedmedicalprod-
uct[17]andthemostdownloadedappofallmelanomascreeningappsintheAndroid
store[12],reachingapproximately900,000usersin2018[18]. SkinVision® [19]indicated
promisingresultswithhighsensitivityandspecificitybyevaluatingthediagnosticaccu-
racyofthismHealthappinriskclassificationofskinlesionsbasedonmachinelearning
algorithmsinaretrospectivestudy[20]. However,someexpertscriticizethatthereported
sensitivity(95.1%)andspecificity(78.3%)oftheSkinVision® appwereprobablyoveres-
Cancers2022,14,3829 3of21
timated in the released studies based on the nature of the study design and sampling
errors[21].
IfmHealthappshavehighdiagnosticaccuracyindistinguishingbenignnevifrom
malignantlesions,thereisgreatpotentialinsupportingindividualswithsuspiciouspig-
mentedskinlesionsintheirdecisiontoconsultadermatologistorinreducingfearofskin
cancer [22]. However, low diagnostic accuracy carries the risk of misinterpretation by
AI,particularlyover-detectionbymistakenlydiagnosingmelanomaandassociateduser
anxiety,aswellasmissingmelanoma,whichleadstofatalconsequences. Theseconcerns
arisefromseveralstudiesthathavedemonstratedpoordiagnosticaccuracyofsmartphone
appsformelanomadetectioncomparedtodermatologists[23–25].
Inadditiontothediagnosticaccuracyofsmartphoneapps,knowledgeaboutlayper-
sons’willingnesstousemHealthappsandtheirpotentialtrustinthesetechnologiesis
relevant. Therefore,healthcareprofessionals’andlaypersons’personalexperiences,expec-
tations,andconcernsregardingtheuseofAIinmelanomadetectionneedtobeanalyzed.
CertainbarrierstomHealthappsmayreducewidespreadacceptancebylaypersonsin-
cludingconsiderationaboutprivacy,costs,andethics,aswellasfearsaboutqualityand
reliability[26–29]. Besidescriticalpatients’perspectivesregardingmHealthappsandAI
inmelanomadetection,beneficialattitudesarebasedonfasterdiagnosis,accesstocare,
usability,andsupportforphysicians[26,27,30,31].
To date, there are no prospective validation studies of this CE-certified melanoma
detectionappcomparingtheriskassessmentswiththoseofdermatologistsandclass1CE-
certified2Dand3Dtotalbodyphotography(TBP)devicesalongsidehistopathology. The
smartphoneappSkinVision®providesonlymacroscopicclose-upimagesoftheskin,while
thedeep-learningalgorithmofthe2Dand3Dconvolutionalneuralnetworks(CNN)uses
dermoscopic images. Data evaluating the smartphone app by patients and physicians
are also sparse. Our study aims to assess the diagnostic accuracy of the CE-certified
smartphoneappSkinVision®inmelanomadetectioninareal-worldsettingandtoprovide
aninsightintohealthcareprofessionals’andlaypersons’evaluationofmHealthappsfor
melanomascreening.
2. MaterialsandMethods
2.1. StudyDesignandParticipants
Weperformedthisprospective,single-center,comparativeobservationalcohortstudy
attheDepartmentofDermatologyattheUniversityHospitalBaselinSwitzerlandbetween
January2021toJune2021. Sevendermatologists(beginners: <2yearsprofessionalexpe-
rience, n = 4; intermediate: 2–5 years professional experience, n = 1; experts: >5 years
professionalexperience, n=2), aswellas114patientswereincludedinthestudywith
an age of ≥18 years with a high risk for developing a primary cutaneous malignant
melanomadefinedaspreviousmelanoma(includingmelanomainsitu),≥100melanocytic
nevi,≥5atypicalnevi,strongfamilyhistoryformelanoma,diagnosisofdysplasticnevus
syndrome,orknownCDKN2Amutation. Exclusioncriteriawereacutepsychiatricillness
oracutecrisisandFitzpatricksigntypeV-VI.
2.2. Procedures
Inthefirststep,thepatientssignedtheinformedconsentaftertheywereinformed
byadermatologistaboutthestudydesignandthefollowingexaminations. Subsequently,
thedermatologistobtainedamedicalhistory,includingahistoryofmelanomatoenable
classificationintothedifferentriskgroups. Theclassificationofallhigh-riskpatientsinto
furtherriskcohortsaredefinedbyhowoftenthepatientsrequireskincancerscreening.
Based on this, we have classified our melanoma patients as high risk, as they come to
dermatological control every 3–12 months according to the corresponding AJCC stage.
Patientswithoutmelanomaintheirownmedicalhistoryareseenevery12months.
Allstudyparticipantsunderwentastandardskincancerscreeningbyadermatologist
(SupplementaryFigureS1). Thepigmentedskinlesionswereassessedwithdermatoscopy
Cancers2022,14,3829 4of21
andclassifiedaseitherbenignormalignant. Thedermatologistdefinedpigmentedskin
lesionsthatweresuspectedmelanomaandindicatedwhetherlesionssmallerthan3mm
shouldbeclassifiedwiththedifferentAImodalitiesduetosuspicion. Theregularskin
cancerscreeningwasperformedbeforeanyAI-basedriskassessmentswereachieved,so
thedermatologistshadnoknowledgeaboutAIclassificationofthemelanocyticlesions
uptothispoint. Inthenextstep,allmelanocyticnevi≥3mmoranysmallersuspicious
melanocyticlesionswereassessedusinganiOS-basediPhoneSEsmartphoneequipped
witha12-megapixelcameraandtheappSkinVision®(SkinVision®B.V.,Amsterdam,the
Netherlands,App-Version6.8.1),whichisbasedonamachine-learningalgorithmclassify-
ingpigmentedlesionsintolow,medium,andhighriskformelanoma. Onlythelesions
classifiedashigh-risk—indicatingarecommendationtoconsultadermatologist—were
recorded. Afterwards,patientsreceivedawhole-bodyscreeningusingthe2Dautomated
totalbodymapping(ATBM®)masterofFotoFinder(FotoFinderATBM®SystemsGmbH,
Bad Birnbach, Germany, Version 3.3.1.0, risk scoring with MoleAnalyzer Pro), and the
3DTBPVectra® WB360System(CanfieldScientific,Parsippany,NJ,USA,Version4.7.1,
risk scoring with DEXI) which was performed by medical students and a study nurse.
Subsequently,alllesionsover3mmoranysmallersuspiciouslesionswereassessedbythe
2Dand3DAIdevicesusingtheirdermoscopes(dermoscopemedicam1000(FotoFinder
ATBM®)andVISIOMED®D200evodermoscope(Vectra®WB360)). Fordermoscopicim-
agedmelanocyticnevi,weobtainedAI-basedriskscoresbetween0.0–1.0for2DFotoFinder
ATBM® and0.0–10.0for3DTBPVectra® WB360. FotoFinder’sATBM® mastercreatesa
2D-imageoftheentiresurfaceofthepatientusing20photostakenfrom8differentparts
ofthebody,whileVectra®WB360generatesa3D-imageusing92individualphotosthat
are converted into a 3D Avatar. Finally, the dermatologists assessed the skin lesions a
secondtimewithknowledgeoftheAIriskassessmentscoresof2DFotoFinderATBM®
and3DTBPVectra® WB360. Thepatientwasinformedaboutthelesionswithsuspicion
formelanomabyadermatologistandaboutthe2Dand3DCNNclassificationsabovethe
study-definedcut-offscores.
The indication for excision of suspicious lesions was based on the dermatologists’
suspicion for melanoma and/or malignancy risk assessment scores of the 2D imaging
toolFotoFinderATBM® and/or3DimagingtoolVectra® WB360indicatingvaluesover
thestudy-definedcut-offscore(>0.5resp. >5.0). Thepatientwasinformedwhichlesions
would be removed with the appropriate rationale. A maximum of two excisions were
performedpervisitandperpatientduetoethicalreasons,withanexceptionforfurther
biopsiesincasesofhigh-gradesuspicionofmalignancybythedermatologistorpatient
request. Thereferencestandardforabenignlesionwaseitherthehistologicaldiagnosis(no
melanoma)orthecombinationofthedermatologist’sevaluation(benignlesion)plusthe
AIscoresoftwoindependentmedicaldevices(FotoFinderATBM® andVectra® WB360)
eachbelowthecut-offscore.
Afteralltheassessments,theparticipatingpatientscompletedananonymous9-item
questionnairethatsurveyedtheirattitudes,personalpreferences,andconcernsaboutthe
useofAIinmelanomadetectioncomparedwithskincancerscreeningsbyadermatologist
inadditiontosociodemographicdata.Thedermatologistscompleteda2-itemquestionnaire
assessingtheirattitudestowardthesmartphoneappinmelanomascreening,whichwas
answered specifically for each of the 114 included patients. Neither the patients nor
dermatologists were informed about the result of the app’s risk assessment due to the
extremelyhighnumberoffalse-positivefindingstopreventresponsebias. Oursurveywas
designeddenovoafterliteratureresearch. Allanswerswereoptional. Thequestionnaire
was available in German, English and French and included binary questions (yes/no),
multiplechoicequestionsandvisualanaloguescales(VAS)withscoresfrom0–10.
2.3. StatisticalAnalysis
ComparisonofcontinuousvariableswastestedwiththeWilcoxonranktest. Com-
parisonofcategoricalvariableswastestedwithFishersExacttest. Ap-valueoflessthan
Cancers2022,14,3829 5of21
0.05wasdeemedassignificant. ReceiverOperatingCharacteristics(ROC)analysiswas
usedtoassesstheperformanceoftheSkinVision®appagainstthecombinedevaluationof
FotoFinderATBM®,Vectra®WB360,andthedermatologistandtheSkinVision®appagainst
histology. AllanalyseswereperformedwithR(version4.1)andvisualizedwithggplot2.
2.4. Ethics
Thestudywasapprovedbythelocalethicscommittee(22020-02482),registeredwith
ClinicalTrials.gov(NCT04605822),andwasconductedincompliancewiththeDeclaration
ofHelsinkiandGoodClinicalPracticeGCP-rules.
3. Results
3.1. StudyPopulation
Overall, data from 114 patients were analyzed, including 55 patients at high-risk
for developing a melanoma (mean age 55 years (age range): 22–85), 47% females) and
59melanomapatients(meanage60years(agerange: 29–81),54%females)(Table1). The
familyhistoryformelanomawaspositivein19%ofthemelanomapatientsandin56%
of the non-melanoma patients. Most of the patients used sunscreen SPF 30–50 (51% of
melanoma patients vs. 62% of patients at high-risk for melanoma) and had previous
sunburnsinchildhood(54%resp. 69%).
Table1.Characteristicsofthestudypopulationandtheirskincancerawareness.
Patientsat
Patientswith
AllPatients, High-Riskfor
Characteristic Melanoma,
N=1141 Melanoma,
N=591
N=551
Age,n(agerange) 59(22–85) 60(29–81) 55(22–85)
Sex,n(%)
Female 58(51%) 32(54%) 26(47%)
Male 56(49%) 27(46%) 29(53%)
Riskprofile,n(%)
Multiplemelanocyticnevi(≥100)
and/ordysplasticnevi(≥5)and/orpositive
familyhistoryformelanomaand/or 55(48%) 0(0%) 55(100%)
diagnosisofdysplasticnevussyndrome
and/orCDKN2Amutation
Previousresectedmelanomainsituor
57(50%) 57(97%) 0(0%)
primarycutaneousmelanoma
Metastaticmelanoma 2(1.8%) 2(3.4%) 0(0%)
Positivefamilyhistoryformelanoma,
42(37%) 11(19%) 31(56%)
n(%)
Frequencyofskincancerscreening,
n(%)
Severaltimesperyear 40(35%) 34(58%) 6(11%)
Every12months 39(34%) 16(27%) 23(42%)
Every1–2years 8(7%) 4(6.8%) 4(7.3%)
Every2years 9(7.9%) 2(3.4%) 7(13%)
Lessthanevery2years 14(12%) 3(5.1%) 11(20%)
Never 4(3.5%) 0(0%) 4(7.3%)
Historyofsunburnsinchildhood,
70(61%) 32(54%) 38(69%)
n(%)
Frequencyofsunburns(Child),n(%)
Rarely(lessthanonceperyear) 44(63%) 20(62%) 24(63%)
Regularly(onceperyear) 22(31%) 10(31%) 12(32%)
Often(morethanonceperyear) 4(5.7%) 2(6.2%) 2(5.3%)
Historyofsunburnsinadulthood,
39(34%) 18(31%) 21(38%)
n(%)
Cancers2022,14,3829 6of21
Table1.Cont.
Patientsat
Patientswith
AllPatients, High-Riskfor
Characteristic Melanoma,
N=1141 Melanoma,
N=591
N=551
Frequencyofsunburns(Adult),n(%)
Rarely(lessthanonceperyear) 38(97%) 18(100%) 20(95%)
Regularly(onceperyear) 0(0%) 0(0%) 0(0%)
Often(morethanonceperyear) 1(2.6%) 0(0%) 1(4.8%)
Previoustanninginthesolarium,
38(33%) 13(22%) 25(45%)
n(%)
Usageofsunscreen(SPF),n(%)
SPF6–10 2(1.8%) 1(1.7%) 1(1.8%)
SPF15–25 10(8.8%) 3(5.1%) 7(13%)
SPF30–50 64(56%) 30(51%) 34(62%)
SPF50+ 38(33%) 25(42%) 13(24%)
1Median(Range);n(%).
A total of 1204 pigmented skin lesions were assessed in this study (Figure 1). In
61cases(5.1%),weperformedahistopathologyexamination,while1129lesions(94%)were
diagnosedtobeclinicallyclearlybenignbasedonthecombinationofariskassessmentby
Cancers 2022, 14, x FOR PEER REVIEW 7 of 23
adermatologistandAI-basedriskscoresbelowthecut-off(2Dand3DTBP)andhadno
indicationforobtaininghistopathology.
FiFgiugruer e1.1 F.lFolwow chcahrat rotfo aflal lilnicnluclduedde dpipgimgmenetnetded sksiknin lelseisoionns saanndd ththeeiri rhhisistotoppaatthhoollooggiiccaall oouuttccoommee..
AIA =I =aratirftiicfiicaila ilnintetlellilgigeennccee; ;TTBBPP == ttoottaall bbooddyy pphhoottooggrraapphhyy..
3.2. DiagnosticAccuracyandPerformanceoftheSmartphoneAppSkinVision®
3.2. Diagnostic Accuracy and Performance of the Smartphone App SkinVision®
3.2.1. ComparisonofallRiskAssessments
3.2.1. Comparison of all Risk Assessments
ThesmartphoneappSkinVision®classified980(81%)lesionsasbenignandindicated
aniT nh ce re s am sea drt rp ish ko fn oe r a mp ep l aS nk oin mV ais inio 2n 2®4 cl (a 1s 9s %if )ie cd as 9 e8 s0 , w(8 h1 i% le) tl he esi do en rs m a as tb oe lon gig isn ts a dn id a gin nd oi sc ea dted
an1 1i9n5cr(e9a9s.3ed% )rilseks iofonrs maselbaennoimgna ainnd 22o4n l(y19n%in)e c(a0s.e7s%, )wahsilseu sthpeic idoeursm. aCtoolnosgeiqsutse ndtilayg,nthoesed
11C9E5 -(c9e9r.t3ifi%e)d leaspiponhsa dasa b2e7n-ifgonld ahnidg hoenrlyra nteinoef (m0.e7l%an)o ams as-ussupsipciicoiuous.s Cleosniosneqsucoenmtplya,r tehdet CoE-
cedrteirfmieadt oalpopg ihstasd. Tah 2e7A-foIlsdc ohriegshoefr trhaete2 Dof amndel3aDnoCmNaN-sudsepviiccieosucsl alesssiiofineds cmoomsptlaerseidon tso adser-
mbaetonligongiasntsd. T47he(3 A.9I% s)colerseiso nosf t(hFeo t2oDFi nandder 3ADT CBMNN®) dreesvpi.ce3s9 c(3la.2s%sif)ileedsi monoss(tV leecstiroan®s WasB b3e6n0i)gn
anads s4u7s (p3i.c9i%ou)s lefosriomnse l(aFnootmoFain(Fdigeru rAeT2B).M®) resp. 39 (3.2%) lesions (Vectra® WB360) as sus-
picious for melanoma (Figure 2).
Figure 2. Comparison of risk assessments with the highest rate of suspected melanoma cases by
the smartphone app (n = 1204).
Cancers 2022, 14, x FOR PEER REVIEW 7 of 23
Figure 1. Flow chart of all included pigmented skin lesions and their histopathological outcome.
AI = artificial intelligence; TBP = total body photography.
3.2. Diagnostic Accuracy and Performance of the Smartphone App SkinVision®
3.2.1. Comparison of all Risk Assessments
The smartphone app SkinVision® classified 980 (81%) lesions as benign and indicated
an increased risk for melanoma in 224 (19%) cases, while the dermatologists diagnosed
1195 (99.3%) lesions as benign and only nine (0.7%) as suspicious. Consequently, the CE-
certified app had a 27-fold higher rate of melanoma-suspicious lesions compared to der-
matologists. The AI scores of the 2D and 3D CNN devices classified most lesions as benign
Cancers2022,14,3829 7of21
and 47 (3.9%) lesions (FotoFinder ATBM®) resp. 39 (3.2%) lesions (Vectra® WB360) as sus-
picious for melanoma (Figure 2).
FFiigguurree 22.. CCoommppaarriissoonn ooff rriisskk aasssseessssmmeennttss wwiitthh tthheeh hiigghheessttr raatteeo offs suussppeecctteeddm meelalannoommaac caasseessb byyt he
stmhea rstmpahrotnpehoapnep a(npp= (1n2 =0 41)2.04).
Amongthe224lesionsclassifiedassuspiciousbySkinVision®,193wereconsidered
clinically benign by the physician and the 2D and 3D CNN AI-risk assessment scores,
whereasfourpigmentedskinlesionswereclassifiedsuspiciousbythesmartphoneapp,
dermatologists,2D,and3DTBPdevices(Table2,SupplementaryTableS1). Theknowledge
ofAI-basedriskassessmentscoresdidnotmeaningfullyaffectdermatologists’classification
ofskinlesions,astheychangedtheirdecisiontowardstheindicationforexcisioninonly
threelesionsthatlaterturnedouttobebenign(Table2).
Table2.Riskassessmentsof1204pigmentedskinlesionsbythesmartphoneappSkinVision®,2D
imagingFotoFinderATBM®,3DimagingVectra® WB360,dermatologists,anddermatologistsin
combinationwithknowledgeofFotoFinderATBM®andVectra®WB360AI-scores.
Characteristic N=12041
SmartphoneappSkinVision®
benign 980(81%)
suspicious 224(19%)
2DImagingFotoFinderATBM®
benign 1157(96%)
suspicious 47(3.9%)
3DImagingVECTRA®WB360
benign 1165(97%)
suspicious 39(3.2%)
Dermatologists
benign 1195(99%)
suspicious 9(0.7%)
Dermatologistsinformedaboutriskassessmentscoresby
FotoFinderATBM®+VECTRA®WB360
benign 1192(99%)
suspicious 12(1.0%)
1n(%);AI=artificialintelligence.
Cancers2022,14,3829 8of21
3.2.2. DiagnosticAccuracyoftheSmartphoneAppBasedontheCombinationofthe
Dermatologist’sEvaluationplustheAIRisk-AssessmentScoresofTwoIndependent
MedicalDevices
Receiveroperatingcharacteristic(ROC)analysisoftheclassificationofbenignandsus-
piciouslesionsoftheSkinVision®appcomparedtothecombinedevaluationofFotoFinder
ATBM®,Vectra® WB360,andthedermatologistshadanareaunderthecurve(AUC)score
of 0.621, sensitivity of 0.41, and specificity of 0.83 (Figure 3). Although the specificity
C ancers 2022, 14, x FOR PEER REVIEW
i s reasonable, the sensitivity is low, thus suggesting that the
SkinVision®9 o af
p
2 p3
has poor
diagnosticaccuracy.
Figure3. Receiveroperatingcharacteristiccurveofthesmartphoneappinrelationtotheresults
Figure 3. Receiver operating characteristic curve of the smartphone app in relation to the results of
thoef ctohmebcionmatbioinn aotfi orinsko afsrsiessksmaesnsetss sbmy ednertmsbatyoldoegrismtsa, tFooltoogFiisntdse,rF AotToBFMin®d, aenrdA VTeBcMtra® ®, WanBd36V0e ctra®WB360
(s(esnesnistiivtiivtyi:t y41:.431%.3, %sp,escpifieccitiyfi:c 8it2y.9:%8)2;. A9%U)C; A= aUrCea =unadreear tuhne dcuerrvteh. ecurve.
33.2..23..3 D.iDagiangonstoics tAicccAucraccuyr aocf ythoef StmhearStpmhaorntep Ahopnpe BAaspedp oBna sHeidstoopnaHthiosltoogpya thology
AAmmonogn 6g16 p1igpmigemnteendt eskdinsk leinsiolenssi oenxasmexinaemdi nhiesdtohloisgtiocalollgyi, cwalel yd,ewteectdedet esicxt emdeslaixnom-elanomas,
m1a9s,m 19e mlaenloancyoctiyctinc envevi,i, 2200 ddyysspplalastsitci cnenvei,v ais, wasellw aes l1l6a osth1e6rwoitshee crlwasissifeiecdl alesssiiofinesd wleersei ons were
ddiaigangonsoesde (dTa(Tbaleb 3le, F3i,gFuirge u1r).e 1).
TTaabblel e3.3 D.iDagiangonstoics taicccuacraccuyr aocf ythoef AthI-ebaAseI-db samseadrtpsmhoanret paphpo nSekianpVpisiSokni®n, V2Dis iiomna®g,in2gD FiomtoaFginindgerF otoFinder
ATBM®, 3D imaging Vectra® WB360, dermatologists, and dermatologists in combination with AI
ATBM®,3DimagingVectra®WB360,dermatologists,anddermatologistsincombinationwithAIin
in melanoma detection based on histopathology: sensitivity and specificity.
melanomadetectionbasedonhistopathology:sensitivityandspecificity.
Melanocytic Dysplastic
Histopathologic Melanocytic DMyeslpalnaostmica, Other *,
N Nevus, Nevus, Melanoma, Other*,
DHiaigstnoopsaisth ologicDiagnosis N Nevus, NNev =u s6, 1 NN = 6= 116 1 N=161
N = 19 1 NN= = 1290 11 N=201
SSmmaratrptphhonone eapappp SkinVision® 61
61
SkinVbiesnioignn® 13(68%) 10(50%) 1(17%) 10(62%)
suspicious 6(32%) 10(50%) 5(83%) 6(38%)
benign 13 (68%) 10 (50%) 1 (17%) 10 (62%)
2DimagingFotoFinderATBM® 61
suspicious 6 (32%) 10 (50%) 5 (83%) 6 (38%)
benign 7(37%) 11(55%) 1(17%) 4(25%)
2D imsaugsipnigc iFooutsoFinder 12(63%) 9(45%) 5(83%) 12(75%)
61
ATBM®
benign 7 (37%) 11 (55%) 1 (17%) 4 (25%)
suspicious 12 (63%) 9 (45%) 5 (83%) 12 (75%)
3D imaging VECTRA®
61
WB360
Cancers2022,14,3829 9of21
Table3.Cont.
Melanocytic Dysplastic
Melanoma, Other*,
HistopathologicDiagnosis N Nevus, Nevus,
N=61 N=161
N=191 N=201
3DimagingVECTRA®WB360 61
benign 18(95%) 9(45%) 1(17%) 8(50%)
suspicious 1(5.3%) 11(55%) 5(83%) 8(50%)
Dermatologists 61
benign 17(89%) 18(90%) 1(17%) 16(100%)
suspicious 2(11%) 2(10%) 5(83%) 0(0%)
Beginner:<2years’work
44 N=15 N=12 N=5 N=13
experience
benign 14(93%) 10(83%) 1(20%) 13(100%)
suspicious 1(6.7%) 2(17%) 4(80%) 0(0%)
Intermediate:2–5years’work
5 N=2 N=3 N=0 N=0
experience
benign 1(50%) 3(100%) 0(0%) 0(0%)
suspicious 1(50%) 0(0%) 0(0%) 0(0%)
Experts:>5years’work
11 N=2 N=5 N=1 N=3
experience
benign 2(100%) 5(100%) 0(0%) 3(100%)
suspicious 0(0%) 0(0%) 1(100%) 0(0%)
Dermatologistsinformedabout
61
AIscores2
benign 16(84%) 17(85%) 1(17%) 15(94%)
suspicious 3(16%) 3(15%) 5(83%) 1(6.2%)
Beginner:<2years’work
N=15 N=12 N=5 N=13
experience
benign 13(87%) 9(75%) 1(20%) 12(92%)
suspicious 2(13%) 3(25%) 4(80%) 1(7.7%)
Intermediate:2–5years’
N=2 N=3 N=0 N=0
workexperience
benign 1(50%) 3(100%) 0(0%) 0(0%)
suspicious 1(50%) 0(0%) 0(0%) 0(0%)
Experts:>5years’work
N=2 N=5 N=1 N=3
experience
benign 2(100%) 5(100%) 0(0%) 3(100%)
suspicious 0(0%) 0(0%) 1(100%) 0(0%)
1n(%);*Other=pigmentedbasalcellcarcinoma,histiocytoma,lentigosolaris,pigmentedseborrhoickeratosis,
folliculitiswithperifolliculitis, collisionaltumor: seborrhoickeratosisandnevus, collisionaltumor: actinic
keratosisandlentigosolaris;2riskassessmentscoresbyFotoFinderATBM®andVECTRA®WB360;AI=artificial
intelligence.
Basedonhistopathology,Figure4representstheriskassessmentsofthedermatolo-
gists,themHealthapp,andthecombinationofAIanddermatologists.BoththeSkinVision®
appandthe2Dand3DCNNdevicesindicatedfor5of6histologicalverifiedmelanomas
(83%sensitivity)anelevatedscoreindicatingsuspicionofmelanoma. Thefalse-negative
rateforallAI-basedmedicaldeviceswas17%. Thethreedifferentfalse-negativeclassified
melanomaswereallsuperficialspreadingstageIAmelanomas—SkinVision®: superficial
spreading melanoma, 0.9 mm Breslow thickness, AJCC stage IA (pT1bN0M0); 3D TBP
Vectra®WB360: superficialspreadingmelanoma,0.3mmBreslowthickness,AJCCstage
IA(pT1aN0M0); 2DTBPFotoFinderATBM®: superficialspreadingmelanoma,0.7mm
Breslow thickness, AJCC stage IA (pT1aN0M0). The true-negative rate for melanomas
(specificity) including melanocytic nevi, dysplastic nevi, and otherwise classified diag-
noseswas60.0%ofthesmartphoneapp,63.6%ofthe3DVectra®WB360imagingdevice,
and40.0%ofthe2DFotoFinderATBM® riskassessmenttool. Dermatologistscorrectly
identifiedfiveofsixmelanomas(83%sensitivity). Thefalse-negativeratewas17%. The
true-negativerateformelanomas(specificity)includingmelanocyticnevi,dysplasticnevi,
andotherwiseclassifieddiagnosesamongalldermatologistswas92.7%. Theperformance
Cancers 2022, 14, x FOR PEER REVIEW 11 of 23
SkinVision®: superficial spreading melanoma, 0.9 mm Breslow thickness, AJCC stage IA
(pT1bN0M0); 3D TBP Vectra® WB360: superficial spreading melanoma, 0.3 mm Breslow
thickness, AJCC stage IA (pT1aN0M0); 2D TBP FotoFinder ATBM®: superficial spreading
melanoma, 0.7 mm Breslow thickness, AJCC stage IA (pT1aN0M0). The true-negative rate
for melanomas (specificity) including melanocytic nevi, dysplastic nevi, and otherwise
classified diagnoses was 60.0% of the smartphone app, 63.6% of the 3D Vectra® WB360
imaging device, and 40.0% of the 2D FotoFinder ATBM® risk assessment tool. Dermatol-
ogists correctly identified five of six melanomas (83% sensitivity). The false-negative rate
Cancers2022,14,3829 was 17%. The true-negative rate for melanomas (specificity) including melanocytic1 0noefv2i1,
dysplastic nevi, and otherwise classified diagnoses among all dermatologists was 92.7%.
The performance of the dermatologists strongly correlated with their professional experi-
oefntchee. Hdeenrmcea, ttohleo gtriustes-pstorsointigvley rcaotersre floart emdewlainthomthae wireprreo gfersesaitoenr afolre xepxpereiretns caen.dH deenrcme,atthoel-
torugies-tpso wsiittihv einrtaetremsfeodriamtee leaxnpoemriaenwceer e(1g0r0e%at esrenfosirtievxiptye)r tcsoamnpdadreerdm toat boelogginisntserws i(t8h0i%nt seernmsei--
dtiivaitteye);x wpehreireenacse t(h1e0 0tr%ues-ennesgitaitvivitey )ractoems wpaerreed sitmobileagr i(n9n3e.3r%s( r8e0s%p.s 9e2n.s5i%tiv siptye)c;ifwichiteyr)e (aTsatbhlee
t3r)u. e-negativeratesweresimilar(93.3%resp. 92.5%specificity)(Table3).
FFiigguurree 44.. HHiissttoollooggyy aanndd ccoorrrreessppoonnddiinnggd diaiaggnnoossisiso offl elessioionnssa asssesessseseddb byyd deremrmataotloolgogisitsst,ss, martphone
aspmpaSrtkpihnoVnisei oanp®p, SaknidnVdeisrimona®to, alongdis dtseramndatAolIo(gnis=ts6 a1n).d AI (n = 61).
Cancers 2022, 14, x FOR PEER REVIEW 12 of 23
Figure5revealsseveralpigmentedskinlesionsthatwerecorrectlyandincorrectly
Figure 5 reveals several pigmented skin lesions that were correctly and incorrectly
classifiedasmelanomasbythesmartphoneappSkinVision®.
classified as melanomas by the smartphone app SkinVision®.
ROC analysis of the classification of melanoma of the SkinVision® app compared to
histology had an area under the curve (AUC) score of 0.717, sensitivity of 0.83, and speci-
ficity of 0.6 (Figure 6). Using histology as the gold standard, the SkinVision® app had high
sensitivity but mediocre specificity.
Figure5.CorrectlyandfalselyclassifiedmelanomasbythesmartphoneappSkinVision®:(A,B).True-
Figure 5. Correctly and falsely classified melanomas by the smartphone app SkinVision®: (A,B).
Trupeo-psiotsiviteivcela cslsaifisseidfiemde lmaneolamnao;m(Ca;, D(C).,DFa)l.s Fe-aplsoes-iptiovseitcilvaess cifilaesdsimfieedla nmoemlaan;o(Em,Fa); .(TEr,uFe).- nTerguaet-inveegcalatisvsiefi ed
clasmsiefileadn ommeala;n(Gom).aF;a (lGse)-.n Feaglaseti-vneegclaatsivsiefi celdasmsiefileadn ommeala.noma.
ROC analysis of the classification of melanoma of the SkinVision® app compared
to histology had an area under the curve (AUC) score of 0.717, sensitivity of 0.83, and
specificityof0.6(Figure6). Usinghistologyasthegoldstandard,theSkinVision®apphad
highsensitivitybutmediocrespecificity.
Figure 6. Receiver operating characteristic curve of the smartphone app in relation to the results of
the histology (sensitivity of 83.3%, specificity 60.0%); AUC = area under the curve.
3.3. Patient Perspective on AI in Melanoma Screening
3.3.1. Confidence in Dermatologists vs. Smartphone App
Most of the patients at high-risk for melanoma (55% (30/55)) and patients with mela-
noma (53% (31/59)) reported being very confident about a mole examination by a derma-
tologist (rating scale 10/10). In contrast, only a minority of high-risk patients (16% (9/55))
Cancers 2022, 14, x FOR PEER REVIEW 12 of 23
Figure 5. Correctly and falsely classified melanomas by the smartphone app SkinVision®: (A,B).
Cancers2022,14,3829 11of21
True-positive classified melanoma; (C,D). False-positive classified melanoma; (E,F). True-negative
classified melanoma; (G). False-negative classified melanoma.
Figure6.Receiveroperatingcharacteristiccurveofthesmartphoneappinrelationtotheresultsof
Figure 6. Receiver operating characteristic curve of the smartphone app in relation to the results of
thehistology(sensitivityof83.3%,specificity60.0%);AUC=areaunderthecurve.
the histology (sensitivity of 83.3%, specificity 60.0%); AUC = area under the curve.
3.3. PatientPerspectiveonAIinMelanomaScreening
3.3. Patient Perspective on AI in Melanoma Screening
3.3.1. ConfidenceinDermatologistsvs. SmartphoneApp
3.3.1. Confidence in Dermatologists vs. Smartphone App
Most of the patients at high-risk for melanoma (55% (30/55)) and patients with
melanMomosat o(5f 3t%he (p3a1t/ie5n9t)s) arte phiogrhte-rdisbke fionrg mveelraynocmonafi (d5e5n%t (a3b0o/5u5t))a amndo lpeateixeanmtsi wnaitthio mneblya-
andoemrma a(5to3l%og (i3s1t/(5r9a)t)in rgepsocartleed1 0b/e1in0g). vInercyo cnotrnafsidt,eonntl yabaomuti nao mriotyleo efxhaimghin-raistikopn abtyie na tdse(r1m6%a-
(9to/l5o5g)i)sat n(rdatminegl asncaolme a10p/a10ti)e. nInts c(o1n2%tra(s7t/, o5n9)ly) fae lmtvineoryritsya foef whihgehn-rbisekin pgaitnievnetsst i(g1a6t%ed (9b/y55a))
smartphoneappalone. Nosignificantdifferenceinratingswasidentifiedbetweenthetwo
riskgroups(p<0.9;p<0.7)(SupplementaryTableS2).
3.3.2. TrustworthinessoftheSmartphoneApp
Allparticipantsprimarilyratedphysicianexamination(100%(55/55)amonghigh-
riskpatients,100%(59/59)amongmelanomapatients)astrustworthy,andthemajority
didsofor2DTBPimaging(93%(51/55)resp. 88%(52/59))and3DTBPimaging(91%
(50/55)resp. 90%(53/59)). Thesmartphoneappwaslessfrequentlyratedastrustworthy,
withonly36%(20/55)amongpatientsathigh-riskformelanomaand49%(29/59)among
melanomapatients(Table4). Theagerevealedasignificantcorrelationwiththeevaluation
ofsmartphones’trustworthiness(p<0.004), witholderpatients(>60yearsold)having
trustedtheappthreetimesmorethanyoungerpatients(≤60yearsold)(Figure7). Neither
previousmelanomavs. high-riskcriteriaformelanomanorsexsignificantlyinfluencedthe
evaluationofthetrustworthinessofthesmartphoneapp.
Cancers2022,14,3829 12of21
Table4.AssessmentoftrustworthinessoftheAI-basedsmartphoneappSkinVision®,2Dimaging
FotoFinderATBM®,and3DimagingVectra®WB360comparedtodermatologists.
Patientsat
Patients
High-Risk
with
Characteristic N for p-Value2
Melanoma,
Melanoma,
N=591
N=551
Thefollowingexaminationwas
trustworthy:Smartphone 114 0.3
appassessment
Yes 29(49%) 20(36%)
No 5(8.5%) 8(15%)
Idon’tknow 23(39%) 22(40%)
Noanswer 2(3.4%) 5(9.1%)
Dermatologistassessment 114
Yes 59(100%) 55(100%)
No 0(0%) 0(0%)
Idon’tknow 0(0%) 0(0%)
Noanswer 0(0%) 0(0%)
2DTBPassessment 114 0.3
Yes 52(88%) 51(93%)
No 0(0%) 0(0%)
Idon’tknow 7(12%) 3(5.5%)
Noanswer 0(0%) 1(1.8%)
3DTBPassessment 114 0.3
Yes 53(90%) 50(91%)
No 0(0%) 0(0%)
Idon’tknow 6(10%) 3(5.5%)
Cancers 2022, 14, x FOR PEER REVIEW Noanswer 0(0%) 2(3.6%) 14 of 23
1n(%);2Fisher’sexacttest;Pearson’sChi-squaredtest;TBP=totalbodyphotography.
FFiigguurree 77.. OOddddss rraattiioo ffoorr vvaarriiaabblleess iinnflfulueennccininggt htheet rturustswtwoortrhthininesessso fofs msmaratrpthpohnoense’sr’i srikska sassessessmsmenetnitn
mine mlaenloamnoamdae tdeectteiocnti.on.
3.3.3. Impact of AI vs. Dermatologists’ Examination on Patients’ Fear of Developing Skin
Cancer
Most participants indicated that an examination by a physician reduced their fear of
developing skin cancer, namely in 89% (49/55) among high-risk patients and 81% (48/59)
among melanoma patients. Comparably, the 2D TBP imaging achieved the same effect in
78% (43/55) resp. 76% (45/59), and the 3D TBP device in 82% (45/55) resp. 75% (44/59). In
contrast, the assessment with the smartphone app appeased fear of skin cancer in only
33% (18/55) of patients at high-risk for melanoma and in 32% (19/59) of patients with mel-
anoma. Indeed, one high-risk patient (1.8%) even reported an increased fear of developing
skin cancer by using the smartphone app (Supplementary Table S2).
3.3.4. Patients’ Subjective Assessment of the Accuracy of AI vs. Dermatologists
Patients expected reliable results with the highest accuracy by both the assessment
by a physician (98% (54/55) among high-risk patients, 92% (54/59) among melanoma pa-
tients) and by the 2D TBP imaging (82% (45/55) resp. 86% (51/59)) as well as the 3D TBP
device (89% (49/55) resp. 88% (52/59)). Only 16% (9/55) of high-risk patients and 31%
(18/59) of melanoma patients expected reliable results from the smartphone app (Supple-
mentary Table S2). No significant differences were identified between the two risk groups
in the evaluations.
3.3.5. Patient Preference for Skin Cancer Screening
Both cohorts favored a combination of dermatologist and 3D TBP risk assessment for
the examination of pigmented skin lesions (64% (35/55) among patients at high-risk for
melanoma, 51% (30/59) among melanoma patients), while neither preferred assessment
by a smartphone app alone (Figure 8A, Supplementary Table S2). The combination of der-
matologist and smartphone app was favored by only 1.8% (1/55) of patients at high-risk
for melanoma and 3.4% (2/59) of patients with melanoma.
Cancers2022,14,3829 13of21
3.3.3. ImpactofAIvs. Dermatologists’ExaminationonPatients’FearofDeveloping
SkinCancer
Mostparticipantsindicatedthatanexaminationbyaphysicianreducedtheirfearof
developingskincancer,namelyin89%(49/55)amonghigh-riskpatientsand81%(48/59)
amongmelanomapatients. Comparably,the2DTBPimagingachievedthesameeffectin
78%(43/55)resp. 76%(45/59),andthe3DTBPdevicein82%(45/55)resp. 75%(44/59). In
contrast,theassessmentwiththesmartphoneappappeasedfearofskincancerinonly33%
(18/55)ofpatientsathigh-riskformelanomaandin32%(19/59)ofpatientswithmelanoma.
Indeed,onehigh-riskpatient(1.8%)evenreportedanincreasedfearofdevelopingskin
cancerbyusingthesmartphoneapp(SupplementaryTableS2).
3.3.4. Patients’SubjectiveAssessmentoftheAccuracyofAIvs. Dermatologists
Patientsexpectedreliableresultswiththehighestaccuracybyboththeassessment
by a physician (98% (54/55) among high-risk patients, 92% (54/59) among melanoma
patients)andbythe2DTBPimaging(82%(45/55)resp. 86%(51/59))aswellasthe3D
TBPdevice(89%(49/55)resp. 88%(52/59)). Only16%(9/55)ofhigh-riskpatientsand
31% (18/59) of melanoma patients expected reliable results from the smartphone app
(SupplementaryTableS2). Nosignificantdifferenceswereidentifiedbetweenthetworisk
groupsintheevaluations.
3.3.5. PatientPreferenceforSkinCancerScreening
Bothcohortsfavoredacombinationofdermatologistand3DTBPriskassessmentfor
theexaminationofpigmentedskinlesions(64%(35/55)amongpatientsathigh-riskfor
Cancers 2022, 14, x FOR PEER REVIEW 15 of 23
melanoma,51%(30/59)amongmelanomapatients),whileneitherpreferredassessment
by a smartphone app alone (Figure 8A, Supplementary Table S2). The combination of
dermatologistandsmartphoneappwasfavoredbyonly1.8%(1/55)ofpatientsathigh-risk
formelanomaand3.4%(2/59)ofpatientswithmelanoma.
Figure8.Cont.
Figure 8. (A) Patient preference for mole assessment (patients at high-risk for melanoma, n = 55;
patients with melanoma, n = 59); (B) Patient preference for AI in skin cancer screening (patients at
high-risk for melanoma, n = 55; patients with melanoma, n = 59).
Regarding patient preference for skin cancer screenings, almost all high-risk patients
(98% (54/55)) and melanoma patients (95% (56/59)) indicated their belief that AI can im-
prove a physician’s diagnostic performance. Most patients (64% (35/55) among high-risk
patients, 54% (32/59) among melanoma patients) would prefer that the physicians would
always consider the result of AI in their diagnosis (Figure 8B) (Supplementary Table S2).
Cancers 2022, 14, x FOR PEER REVIEW 15 of 23
Cancers2022,14,3829 14of21
Figure8. (A)Patientpreferenceformoleassessment(patientsathigh-riskformelanoma,n=55;
Figurpea 8ti.e n(Ats)w Pitahtmieenlat npormeafe,nre=n5c9e) ;f(oBr) Pmatoielen tapsrseefesrsemnceenfot r(ApaItiniesnktisn caatn hceigrhsc-rreiesnki nfgo(rp matieenlatsnaotma, n = 55;
patienhtisg hw-riisthk fmoremlaenlaonmomaa, ,nn == 5559;)p; a(tBie)n tPsawtiiethnmt pelraenfoemrean,nce= f5o9r). AI in skin cancer screening (patients at
high-risk for melanoma, n = 55; patients with melanoma, n = 59).
Regardingpatientpreferenceforskincancerscreenings,almostallhigh-riskpatients
(98%(54/55))andmelanomapatients(95%(56/59))indicatedtheirbeliefthatAIcanimprove
Regarding patient preference for skin cancer screenings, almost all high-risk patients
aphysician’sdiagnosticperformance.Mostpatients(64%(35/55)amonghigh-riskpatients,
(98%5 (45%4/(5352/))5 9a)nadm moneglamneolamnoam paaptaietinentsts )(9w5o%ul d(5p6r/e5fe9r))t hiantdthiceaptehdys itchiaenisr wbeoluiledf atlhwaaty As I can im-
proveco an spidheyrsthiceiraensu’slt dofiaAgIninotshteicir pdeiargfnoorsmisa(Fnicgeu.r eM8Bo)s(tS uppaptileemnetsn t(a6ry4%Ta b(l3e5S/25)5.) among high-risk
patients, 54% (32/59) among melanoma patients) would prefer that the physicians would
3.3.6. Dermatologists’PerspectiveofSmartphoneAppsforMelanomaScreening
always consider the result of AI in their diagnosis (Figure 8B) (Supplementary Table S2).
Amongthesevendermatologists,theystatedinonly5.3%oftheskincancerscreenings
(6/114)thatthesmartphoneappincreaseddiagnosticconfidenceandinonly8.8%ofthe
assessments(10/114)theytrustedtheapp(SupplementaryTableS3).
4. Discussion
4.1. DiagnosticAccuracyandPotentialConsequencesoftheSmartphoneAppSkinVision®
In this prospective validation study of the CE-certified mHealth app SkinVision®
basedonadeeplearningalgorithm,weobservedalowdiagnosticaccuracyindetecting
melanoma. Thesmartphoneapp’ssensitivityvariedbetween41.3–83.3%,thespecificity
between60.0–82.9%,andtheAUROCbetween0.62–0.72%accordingtothestudy-defined
goldstandardsofhistopathologyresp. combinationofdermatologists’,2D,and3Drisk
assessments. Theapp’sassessmentclassifiedpigmentedskinlesions27timesmoreoften
assuspiciousthanthedermatologists’evaluation. Itisimportanttorecognizethattheapp
onlyprovidesriskstratification,notdiagnosis. However,ifonlytheapp’sassessmentwere
consideredinestablishingadiagnosis,thiswouldresultinanexcisionrateofskinlesions
that is several times higher compared to the dermatologists’ evaluation. Notably, even
dermatologiststypicallyhavealowthresholdforexcisionoflesions,leadingtoanumber
neededtotreat(NNT)formelanomadiagnosisof9.60[32]. Extrapolatingourresultsbased
Cancers2022,14,3829 15of21
onthisnumber,theSkinVision®appmayleadtodramaticratesofover-detection(NNTfor
diagnosisofmelanoma259.20)andthusneedlessmorbidity.
SincetheincorporationofAItechnologyhasbecomeavailableinsmartphoneappsfor
laypersonsandthusmaypotentiallyreplaceamedicalconsultation,concernsaboutrelia-
bilityanddiagnosticaccuracyarerising. Previousstudieshavecontroversiallydiscussed
thediagnosticperformanceofSkinVision®andothersmartphoneappsformelanomade-
tectionduetohighvariabilityintheirdiagnosticaccuracy[15,33–35]. Aprospectivestudy
evaluatingthediagnosticaccuracyofSkinVision® comparedtodermatologists’clinical
diagnoses and histological results demonstrated that the smartphone app was inferior
tothediagnosticperformanceofdermatologistswithasensitivityof73%vs. 88%anda
specificityof83%vs. 97%[36]. Basedonthehistopathologicalreferencestandard,theapp
achievedaslightlyhighersensitivityof83%inourstudy,whilethespecificitywaslowerat
60%. Thehighcountofdysplasticneviinourfindingscouldhaveposeddifficultiesforthe
app’salgorithmindichotomousclassification(riskclassificationfornevusvs. melanoma),
whichcouldexplainthelowspecificitydeterminedonhistologyinourresults. Arecent
prospectivemulticenterdiagnosticaccuracystudyofSkinVision®including785lesionsin-
dicatedasensitivityof89.8%andaspecificityof32.9%fortheapp’salgorithmbasedonthe
histopathologicaloutcome[37]. Comparedtothehistology,weobtainedsimilarresultsfor
sensitivity. Nevertheless,thespecificitywassuperiorinourstudy. Aprospectivestudyex-
aminingtheeffectivenessofthreemelanomaappsinriskstratificationofpigmentedlesions
alsorevealedlowratesofsensitivity(56.8%)andspecificity(50%)fortheSkinVision®app
oniOSdevices[33]. Contrarytotheseresults,theapp’ssensitivityinourstudyachieved
41% compared to the gold standard of the combination of dermatologists plus 2D and
3Driskassessmentscores. Theevenlowersensitivityinourstudycomparedwithother
findingscouldbeexplainedbythedesignofourstudy,whichrepresentedareal-world
settingwithawidevariabilityoflesionsandincorporatedahighnumberofbenignskin
lesions(melanocyticanddysplasticnevi)and,comparatively,asmallercountofmelanomas.
However,arecentstudyinvestigatingtheaccuracyofthesmartphoneappSkinVision® for
riskassessmentofskinlesionsrevealedasensitivityof95.1%andaspecificityof78.3%
forthedetectionofmalignantorpremalignantlesions,whichthusindicatesapromising
result[20]. Nevertheless, someexpertshavealreadycriticizedthefindingsasprobably
overestimatedduetothenatureofthestudydesignandsamplingerrors[21]. Considering
theapp’sassumedsensitivityofaround95%andspecificityofapproximately80%ina
low prevalence setting, for example in the UK with an incidence of 257 per 100,000 for
non-melanomaskincancer,theappwouldhaveapositivepredictivevalueofonly1.2%,
whichwouldresultin20,000false-positiveoutcomesper100,000users[22]. Puttingour
resultsintoperspectivewiththepublishedstudywithahighrateoffalse-positivescores,
wealsoperceivethelatter’sresultstobeoverestimatedandnotrepresentative.
Asidefromweaknessesintheperformanceoftheapp’salgorithm,weconsidermacro-
scopicimagesasthemajorlimitationinthesmartphoneappforclassifyingskinlesions.
Under the current conditions, clinical close-up dermoscopic images are needed for the
mostaccuratediagnosisbothwhenevaluatedbyaphysicianandbyanAI-basedalgorithm.
Theinvestigatedapponlyreferstomacroscopicimages,butalreadyavailablesmartphone
magnifying glass attachments could provide more detailed images. However, such an
implementationoftheseattachmentsinvolvesadditionalexpensivecostsforlaypersonsin
thecontextofanindependentscreeningviaappandpotentialhandlingchallenges.
Aprospective,multicenterstudyincluding1550imagesofskinlesionsacquiredwith
smartphoneanddigitalsingle-lensreflexcamerasinvestigatedtheaccuracyindetecting
melanoma of an AI-based algorithm trained using previously published dermoscopic
images[38]. ThealgorithmachievedanAUROCof90.1%forbiopsiedlesionsand95.8%
forcontrollesions,asensitivityof100%,andaspecificityof64.8%forimagesobtainedwith
aniPhone. Comparedtotheseresultsindermoscopicimages,thedeep-learningalgorithm
ofthesmartphoneappSkinVision®revealeddecreaseddiagnosticaccuracyinmelanoma
recognitionbasedonmacroscopicimagesinourstudywithanAUROCof62–72%. The
Cancers2022,14,3829 16of21
studybyPhillipsetal. exemplifiesthatmostresearchonthediagnosticperformanceof
AI-basedalgorithmfocusesondermoscopicimages,whiletheaccuracyofmacroscopic
imagesinmelanomadetectionislowerandlessstudied.
The dermatologists in our study demonstrated high diagnostic accuracy in terms
of specificity (92.7%; beginners: 92.5% vs. experts: 93.3%), which is consistent with
other findings [36]. As might have been expected, the comparatively lower sensitivity
of all dermatologists (83%) was dependent on professional experience (beginners: 80%
vs. experts: 100%). Thus, compared with the diagnostic accuracy of the smartphone
app,thedermatologistsinourstudyperformedequallyindetectingmelanomaregarding
sensitivity. The different levels of sensitivity and specificity among the dermatologists
can be explained by the years of professional experience. Dermatologists with longer
professionalexperiencehaveclassifiedmorepigmentedskinlesionscorrectlyaccordingto
theirmalignancyriskthandermatologistswithlessprofessionalexperience. Therefore,the
errorrateintheclassificationofmelanomaishigherinnovicepractitioners. Incontrast
to the app, which classifies according to a machine-learning algorithm, the diagnostic
accuracyofdermatologistsseemstocorrelatewiththenumberofself-classifiedlesions.
However,thespecificityofdermatologistswassignificantlyhighercomparedtotheapp’s
AI-basedriskassessment. Eventhoughourstudywasunderpoweredtorevealarelevant
advantage in the combination of dermatologists and artificial intelligence, we suggest
that at least beginners might benefit from AI-based risk assessments in the near future.
Futurestudiesshouldaimtooptimizediagnosticaccuracyinearlymelanomadetection
by synergistically leveraging the high specificity of dermatologists with the diagnostic
performanceofAI-basedtechnologies.
Ontheonehand,asignificantriskposedbythelowspecificityofsmartphoneappsis
over-detection,leadingtomisclassificationofbenignpigmentedskinlesionsasmelanoma.
Weintendtoraiseawarenessthatfalse-positivelesionscouldleadtounnecessarysurgical
interventions, overextensionofthehealthsystem, aswellasanxietyandpsychological
distressforpatients. Ontheotherhand,whenapplyingappswithlowsensitivityanda
highfalse-negativerate,underdiagnosisofmelanomasinsomecasesisanobviousrisk[34].
Thismightconveyafalsesenseofsecuritytopatientsanddiscouragethemfromseeinga
dermatologist,whichislikelytoresultinfatalconsequences. Wesuggestthatlaypersons
shouldusenewsmartphone-basedscreeningtoolswithextremecautionintheabsenceof
robustevidence-basedvalidationstudies,astheymaycausepotentialharmtotheuser.
Arecentsystematicreviewaboutthediagnosticaccuracyofalgorithm-basedsmart-
phone apps for assessing skin cancer risk has criticized the fact that many diagnostic
accuracystudieshaveweakevidenceduetopoorstudydesignandthusdonotsupport
theimplementationofthecurrentapps[15]. TheCEmedicaldeviceclassification1that
was applied for SkinVision® may be inadequate [39]. Although it is non-invasive and
doesnottransferenergyinthebody,thedecision-supportthattheappprovidescanhave
drasticclinicalconsequencesandthusthepublicisnotprotectedsufficientlyfrompotential
risks. TheFDA,ontheotherhand,enforcesamorerigorousapprovalprocess[22]andhas
authorizedonlyoneappformelanomariskstratificationthusfar[16]. Regulatedapproval
ofmHealthappsaccordingtoanevidence-basedprocessisparticularlyimportant,asthey
influencelaypersonsintheirdecision-makingprocessregardingfurthermedicaladvicein
apotentiallyfataldisease[22].
Althoughdeeplearningalgorithmsforskincancerscreeninginappsarecontinuously
evolving,wesuggestwithourfindingsthatmHealthappsshouldnotcurrentlyreplace
face-to-faceconsultationwithadermatologist.
4.2. TheLayandDermatologistPerspectivesontheUseofSmartphoneAppsandOtherAIDevices
inMelanomaScreening
AcceptancebybothdoctorsandpatientsiscrucialforthesuccessfuluseofmHealth
apps in daily life. Regarding laypersons’ perspectives towards the use of smartphone
appsinmelanomariskstratification,weobservedapoorratingoftheapp’sdiagnostic
Cancers2022,14,3829 17of21
accuracy compared to the dermatologists’ examinations. Furthermore, the minority of
patientstrustedtheapp(49%resp. 36%). Overall,mostpatientspreferredthecombination
of dermatologist and AI devices applied by physicians for skin cancer screenings and
perceived AI to support dermatologists’ diagnostic performance. The sole use of the
smartphone app was not favored for skin cancer screening. However, dermatologists
remainedmorecriticaloftheuseofsmartphoneappsthantheirpatients,trustingtheapp’s
riskassessmentinonly8.8%ofexaminations.
Thegenerallyinferiorratingofthesmartphoneappbypatientscouldbeexplained
byseveralfactors. Alackofskillsaswellasconcernsaboutdatausemightnegatively
influencepatients’assessment[40]. OurresultsareinaccordancewithSangersetal.,who
consideredtheuntrustworthinessofmHealthappsandthepreferenceforaphysician
insteadofasmartphoneappinmelanomadetectionasapossiblebarrier[26]. Contrary
to our assumptions, older patients (>60 years) revealed higher confidence in the app
in our findings, which might be related to greater awareness and sensitization of the
disease in older age. However, other studies indicated that younger patients have
morepositiveattitudestowardsmartphoneappsformelanomadetectioncomparedto
elderly patients [40,41]. Whereas in a web-based questionnaire study on the patient
perspectiveofAIinskincancerdiagnostics,therewasnosignificantdifferencebetween
age groups [31]. Regarding the evaluation of smartphone apps’ trustworthiness for
melanomarecognition,ourfindingsdemonstratedatendencyforfemalestohavemore
confidence in the app compared to men. In contrast to our results, previous studies
have revealed a gender-specific correlation in the assessment of mHealth apps with
more males convinced of the technology [40,41]. A cross-sectional study including
200 patients represented significantly lower agreement on whether skin cancer apps
couldcomplementapersonalskinexaminationbyaphysicianwithonly42.6%,while
98% of high-risk patients and 95% of melanoma patients in our study affirmed this
thesisfortheuseofAIinmelanomascreening[41]. Ourresultsareinaccordancewitha
2020publishedstudyexaminingthepatientperspectiveofAIinskincancerdiagnosis
among298participants,with94%ofthesurveyedpatientssupportingtheuseofAIasa
physicianassistancesystem[31].
Weassumethatpatientswithahistoryofmelanomaindicatingthattheyaremore
confident in the app compared to patients at high-risk for melanoma might be based
onahigherawarenessofregularskinexaminationsduetotheirpersonalhistoryalong
withanincreasedwillingnesstointegratesmartphoneappsintotheirindependentskin
examination. Our findings are in line with a cross-sectional study demonstrating that
patientswithapersonalhistoryofmelanomahadamorepositiveattitudetowardtheuse
ofsmartphoneappsthannon-melanomapatients[41].
Mostpatientsinourstudywouldpreferaskincancerscreeningbyacombination
of dermatologists and AI, especially 3D and 2D CNN devices and not mHealth apps,
emphasizing the lack of smartphone app’s acceptance. Computer-aided noninvasive
diagnostic systems based on dermoscopic images and neural networks have recently
alreadyachievedcomparableperformancecomparedtodermatologistsunderexperimental
conditions[42]. OurfindingssuggestthatpatientsperceivegreatbenefitfromAIinskin
cancerscreeningandthatAIcanassistdermatologists[30,43]. However,acceptanceseems
to be closely linked to the assumption that the decision-making of computer-assisted
diagnosticsystemsisreliable,transparent,andcomprehensible[31,44].
Regarding physicians’ attitudes toward the use of smartphone apps in melanoma
detection,wedetectedanevenmorecriticalattitudecomparedtotheparticipatingpatients.
Jandaetal. reportedhighersatisfactionwhenevaluatinghealthcarepractitioners’perspec-
tivesonstore-and-forwardteledermoscopyservicesforthediagnosisofskincancer. 52%
oftheparticipantsindicatedthatmobileteledermoscopycouldimprovethequalityoftheir
patientcare,whereas,inoursurveyonly5.3%perceivedanincreaseindiagnosticaccuracy
bysmartphoneapps[45]. ThelowconfidenceofdermatologistsinmHealthappscould
beduetofearedadditionalworkload, technicalproblems, orequipmentcosts[45]. We
Cancers2022,14,3829 18of21
particularlyemphasizethelimitationsofappsintermsofqualityofimagesandalgorithms,
reliability, false reassurance for concerning lesions and unnecessary for benign lesions,
patientsafetyandsecurity,andadditionalcostsaspotentialconcerns.
Based on robust validation studies, we encourage dermatologists to inform their
patientsabouttheadvantagesanddisadvantagesofavailableappsformelanomascreening.
4.3. StrengthsandLimitations
Thestrengthsofthisstudyarethereal-worldsetting,thesizeoftheincludedlesions
(>1000),andthevalidationofamarket-approvedAI-basedmHealthapp. Anotherstrength
isthatwedidnotonlyconsiderthedermatologist’sassessmentasareferencestandard
besideshistologybutcombinedthephysician’sassessmentwiththeAI-basedriskscoresof
the2Dand3DTBPdevices. However,duetocertainlimitations,thegeneralizabilityof
theresultsshouldbeconsideredwithcaution. Limitationsofourstudyarethatphotos
were taken by medically trained staff at the hospital and not by patients themselves at
home. Histologywasnotavailableforalllesionsduetoahighnumberoffalse-positive
findingsreportedbytheapp,whichwouldhaveresultedina27-foldexcessiveexcisionrate.
Anotherlimitationisthatdermatologistsincombinationwith2Dand3DCNNclassification
asagoldstandardcarriestheriskofmissingmelanoma. Thenumberofmelanomaswas
relativelylowinthisstudy. WehaveonlyimagedpigmentedskinlesionswithaniOS-
basedsmartphoneandthereforecouldnotverifypossibledifferencesindiagnosticaccuracy
betweeniOSandAndroiddevices.Furthermore,biasduetoapreselectedcohortofpatients
athigherriskofmelanomacannotbeexcluded. Furthercomparativestudiesofdifferent
smartphone apps with adequate power for detecting the sensitivity and specificity of
melanomadetectionareneeded.
5. Conclusions
Ourstudyrevealedaworryingover-detectionofsuspiciouslesionsbythemHealth
app SkinVision® as well as inferior diagnostic accuracy in melanoma detection in clin-
ical practice. Thus, the app is not as reliable as previously advertised and indeed may
potentiallycauseharmbymakingusersfeeluncertainandoverwhelmingthehealthsys-
tem. Furthermore, the acceptance among both patients and dermatologists was scarce
for the AI-based smartphone app. Although we suggest that smartphone apps should
currentlynotreplacediagnosisbyadermatologist,westillbelievethatAIhasthepotential
tosupportphysiciansingradingpigmentedskinlesions. Underthecurrentcircumstances,
dermoscopyisneededtoachievethemostaccuratediagnosisbyhumanorAI.Itwillbeour
taskasdermatologiststobalancetheconsequencesoftheAIdecisionsupporttoreachan
optimalnumberneededtotreat,andwewillneedprospectivestudiestoachievethis.Given
thewidespreaduseofsmartphones,algorithm-basedmHealthappsformelanomarecogni-
tionmightalsobeapotentialmediumtoincreaseawarenessformelanomascreeningin
thelaypopulation. However,furtherrobustclinicalevidenceiscrucialbeforeincluding
market-approvedappsinself-examinationbylaypersonsforpublichealthbenefits. We
encouragehealthcareprofessionalstoadvisecautionandavoidpotentialharmaslongas
solidprospectiveevidenceforamelanoma-detectionappislacking.
Supplementary Materials:Thefollowingsupportinginformationcanbedownloadedat: https://
www.mdpi.com/article/10.3390/cancers14153829/s1,TableS1:Combinationofallriskassessmentsof
1204pigmentedskinlesionsbythesmartphoneappSkinVision®,2DimagingFotoFinderATBM®,
3DimagingVectra® WB360,dermatologistsanddermatologistsincombinationwithknowledge
ofFotoFinderATBM®andVectra®WB360AI-scores;TableS2:Patients’preferenceforskincancer
screeningandtheirassessmentoftheAI-basedsmartphoneappSkinVision®,2DimagingFotoFinder
ATBM®,and3DimagingVectra®WB360comparedtodermatologists;TableS3:Dermatologists’per-
spectiveofsmartphoneappsformelanomascreening;FigureS1:Flowchartofthestudyprocedures.
CNN=Convolutionalneuralnetwork,TBP=Totalbodyphotography,AI=Artificialintelligence.
Cancers2022,14,3829 19of21
AuthorContributions: Conceptualization,L.V.M.andA.A.N.;datacuration,S.E.C.,L.K.,S.M.H.,
M.K.,S.S.,A.D.N.andL.V.M.;formalanalysis,P.F.C.,A.S.J.andL.V.M.;investigation,S.E.C.,L.K.,
S.M.H., M.K. and L.V.M.; methodology, L.V.M., A.S.J. and P.F.C.; resources, L.V.M. and A.A.N.;
writing—originaldraftpreparation,A.S.J.,P.F.C.andL.V.M.;writing—reviewandediting,A.S.J.,
A.A.N.,S.E.C.,L.K.,S.M.H.,M.K.,J.-T.M.,R.D.,S.S.,A.D.N.,M.P.L.,P.F.C.andL.V.M.;visualization,
P.F.C.,A.S.J.andL.V.M.;supervision,L.V.M.;projectadministration,L.V.M.;fundingacquisition,
L.V.M.andA.A.N.Allauthorshavereadandagreedtothepublishedversionofthemanuscript.
Funding: This research project was fully funded by the Department of Dermatology, as well as
in minor part by Research Foundation for Young Researchers Grant of the University of Basel,
Switzerland, andbytheVoluntaryAcademicSocietyGrant, Basel, Switzerland. Nofundingby
companiesproducingthetestedproductswasreceived,nordidcompanieshavetheopportunityto
commentorinfluencethemanuscript.
Institutional Review Board Statement: The study was approved by the local ethics committee
(22020-02482),registeredwithClinicalTrials.gov(NCT04605822)andwasconductedincompliance
withtheDeclarationofHelsinkiandGoodClinicalPracticeGCP-rules.
InformedConsentStatement:Informedconsentwasobtainedfromallsubjectsinvolvedinthestudy.
DataAvailabilityStatement:Fullyanonymizeddatacanberequestedfromthecorrespondingauthor.
Acknowledgments:Specialthanksgotoallparticipantswhovoluntarilyparticipatedinthisstudy
andmadesuccessfulimplementationofthisstudypossible.L.V.M.gratefullyacknowledgessupport
fromtheResearchFoundationforYoungResearchersGrantoftheUniversityofBasel,Switzerland
andbytheVoluntaryAcademicSocietyGrant,Basel,Switzerland.
ConflictsofInterest:A.S.J.declaresnoconflictofinterest.A.A.N.declaresbeingaconsultantand
advisorand/orreceivingspeakingfeesand/orgrantsand/orservedasaninvestigatorinclinical
trialsforAbbVie,Almirall,Amgen,Biomed,BristolMyersSquibb,BoehringerIngelheim,Celgene,Eli
Lilly,Galderma,GlaxoSmithKline,LEOPharma,Janssen-Cilag,MSD,Novartis,Pfizer,PierreFabre
Pharma,Regeneron,Sandoz,Sanofi,andUCB.S.E.C.declarenoconflictofinterest.L.K.hasreceived
speakingfeesinapresentationsponsoredbyBoehringerIngelheim.S.M.H.declaresnoconflictsof
interest.M.K.declaresnoconflictsofinterest.J.-T.M.isandhasservedasadvisorand/orreceived
speakingfeesand/orparticipatedinclinicaltrialssponsoredbyAbbVie,Almirall,Amgen,BMS,
Celgene,EliLilly,LEOPharma,Janssen-Cilag,MSD,Novartis,Pfizer,PierreFabre,Roche,Sanofi,and
UCB.R.D.hasintermittent,projectfocusedconsultingand/oradvisoryrelationshipswithNovartis,
MerckSharp&Dhome(MSD),Bristol-MyersSquibb(BMS),Roche,Amgen,Takeda,PierreFabre,Sun
Pharma,Sanofi,Catalym,SecondGenome,Regeneron,Alligator,T3Pharma,MaxiVAXSA,Pfizer,
andtouchIMEoutsidethesubmittedwork. S.S.declaresnoconflictofinterest. A.N.declaresno
conflictofinterest.M.P.L.receivesprojectspecificresearchsupport,outsidethescopeisthiswork,
fromRoche,Novartis,MolecularPartners,andOncobit.P.F.C.declarenoconflictofinterest.L.V.M.
hasservedasadvisorand/orreceivedspeakingfeesand/orparticipatedinclinicaltrialssponsored
byAlmirall,Amgen,BMS,Celgene,EliLilly,MSD,Novartis,PierreFabre,Roche,andSanofi.
References
1. Chacón,M.;Pfluger,Y.;Angel,M.;Waisberg,F.;Enrico,D.UncommonSubtypesofMalignantMelanomas:AReviewBasedon
ClinicalandMolecularPerspectives.Cancers2020,12,2362.[CrossRef]
2. Leiter,U.;Keim,U.;Garbe,C.EpidemiologyofSkinCancer:Update2019.Adv.Exp.Med.Biol.2020,1268,123–139.[CrossRef]
3. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Rutkowski, P.; Lao, C.D.; Cowey, C.L.; Schadendorf, D.; Wagstaff, J.;
Dummer,R.;etal.Five-YearSurvivalwithCombinedNivolumabandIpilimumabinAdvancedMelanoma.N.Engl.J.Med.2019,
381,1535–1546.[CrossRef][PubMed]
4. Hamid,O.;Robert,C.;Daud,A.;Hodi,F.S.;Hwu,W.J.;Kefford,R.;Wolchok,J.D.;Hersey,P.;Joseph,R.;Weber,J.S.;etal.Five-year
survivaloutcomesforpatientswithadvancedmelanomatreatedwithpembrolizumabinKEYNOTE-001.Ann.Oncol.2019,30,
582–588.[CrossRef][PubMed]
5. Robert,C.;Grob,J.J.;Stroyakovskiy,D.;Karaszewska,B.;Hauschild,A.;Levchenko,E.;ChiarionSileni,V.;Schachter,J.;Garbe,C.;
Bondarenko,I.;etal.Five-YearOutcomeswithDabrafenibplusTrametinibinMetastaticMelanoma.N.Engl.J.Med.2019,381,
626–636.[CrossRef]
6. Ahmed,B.;Qadir,M.I.;Ghafoor,S.MalignantMelanoma:SkinCancer-Diagnosis,Prevention,andTreatment.Crit.Rev.Eukaryot.
GeneExpr.2020,30,291–297.[CrossRef]
Cancers2022,14,3829 20of21
7. Swetter,S.M.;Tsao,H.;Bichakjian,C.K.;Curiel-Lewandrowski,C.;Elder,D.E.;Gershenwald,J.E.;Guild,V.;Grant-Kels,J.M.;
Halpern,A.C.;Johnson,T.M.;etal.Guidelinesofcareforthemanagementofprimarycutaneousmelanoma.J.Am.AcadDermatol.
2019,80,208–250.[CrossRef]
8. Anderson,M.TechnologyDeviceOwnership: 2015. Availableonline: https://www.pewresearch.org/internet/2015/10/29
/technology-device-ownership-2015/(accessedon21July2021).
9. PewResearchCenter.MobileFactSheet.Availableonline:https://www.pewresearch.org/internet/fact-sheet/mobile/(accessed
on30July2021).
10. Al-Azzam,M.K.ResearchontheImpactofmHealthAppsonthePrimaryHealthcareProfessionalsinPatientCare.Appl.Bionics
Biomech.2021,2021,7611686.[CrossRef]
11. Flaten,H.K.;StClaire,C.;Schlager,E.;Dunnick,C.A.;Dellavalle,R.P.Growthofmobileapplicationsindermatology—2017
update.Dermatol.OnlineJ.2018,24,1–4.[CrossRef]
12. Ngoo,A.;Finnane,A.;McMeniman,E.;Soyer,H.P.;Janda,M.FightingMelanomawithSmartphones:ASnapshotofWhereWe
areaDecadeafterAppStoresOpenedTheirDoors.Int.J.Med.Inform.2018,118,99–112.[CrossRef]
13. Ouellette,S.;Rao,B.K.UsefulnessofSmartphonesinDermatology:AUS-BasedReview.Int.J.Environ.Res.PublicHealth2022,
19,3553.[CrossRef][PubMed]
14. Kassianos,A.P.;Emery,J.D.;Murchie,P.;Walter,F.M.Smartphoneapplicationsformelanomadetectionbycommunity,patient
andgeneralistclinicianusers:Areview.Br.J.Dermatol.2015,172,1507–1518.[CrossRef]
15. Freeman,K.;Dinnes,J.;Chuchu,N.;Takwoingi,Y.;Bayliss,S.E.;Matin,R.N.;Jain,A.;Walter,F.M.;Williams,H.C.;Deeks,J.J.
Algorithmbasedsmartphoneappstoassessriskofskincancerinadults:Systematicreviewofdiagnosticaccuracystudies.BMJ
2020,368,m127.[CrossRef]
16. Jaworek-Korjakowska,J.;Kleczek,P.eSkin:StudyontheSmartphoneApplicationforEarlyDetectionofMalignantMelanoma.
Wirel.Commun.Mob.Comput.2018,2018,5767360.[CrossRef]
17. Kent,C.NewAnalysisRaisesConcernsoverAccuracyofSkinCancerRiskApps.Availableonline:https://www.medicaldevice-
network.com/news/skin-cancer-apps/(accessedon28May2022).
18. deCarvalhoDelgadoMarques,T.;Noels,E.;Wakkee,M.;Udrea,A.;Nijsten,T.Developmentofsmartphoneappsforskincancer
riskassessment:Progressandpromise.JMIRDermatol.2019,21,e13376.[CrossRef]
19. SkinVision.Availableonline:https://www.skinvision.com/(accessedon25July2021).
20. Udrea, A.; Mitra, G.D.; Costea, D.; Noels, E.C.; Wakkee, M.; Siegel, D.M.; deCarvalho, T.M.; Nijsten, T.E.C.Accuracyofa
smartphoneapplicationfortriageofskinlesionsbasedonmachinelearningalgorithms.J.Eur.AcadDermatol.Venereol.2020,34,
648–655.[CrossRef]
21. Deeks,J.J.;Dinnes,J.;Williams,H.C.SensitivityandspecificityofSkinVisionarelikelytohavebeenoverestimated.J.Eur.Acad
Dermatol.Venereol.2020,34,e582–e583.[CrossRef]
22. Matin,R.N.;Dinnes,J.AI-basedsmartphoneappsforriskassessmentofskincancerneedmoreevaluationandbetterregulation.
Br.J.Cancer2021,124,1749–1750.[CrossRef]
23. Thissen,M.;Udrea,A.;Hacking,M.;vonBraunmuehl,T.;Ruzicka,T.mHealthAppforRiskAssessmentofPigmentedand
NonpigmentedSkinLesions-AStudyonSensitivityandSpecificityinDetectingMalignancy.Telemed.e-Health2017,23,948–954.
[CrossRef][PubMed]
24. Chung,Y.;vanderSande,A.A.J.;deRoos,K.P.;Bekkenk,M.W.;deHaas,E.R.M.;Kelleners-Smeets,N.W.J.;Kukutsch,N.A.
Pooragreementbetweentheautomatedriskassessmentofasmartphoneapplicationforskincancerdetectionandtheratingby
dermatologists.J.Eur.Acad.Dermatol.Venereol.2020,34,274–278.[CrossRef]
25. Nabil,R.;Bergman,W.;Kukutsch,N.A.Conflictingresultsbetweentheanalysisofskinlesionsusingamobile-phoneapplication
andadermatologist’sclinicaldiagnosis:Apilotstudy.Br.J.Dermatol.2017,177,583–584.[CrossRef][PubMed]
26. Sangers,T.E.;Wakkee,M.;Kramer-Noels,E.C.;Nijsten,T.;Lugtenberg,M.Viewsonmobilehealthappsforskincancerscreening
inthegeneralpopulation:Anin-depthqualitativeexplorationofperceivedbarriersandfacilitators.Br.J.Dermatol.2021,185,
961–969.[CrossRef][PubMed]
27. Blum,A.;Bosch,S.;Haenssle,H.A.;Fink,C.;Hofmann-Wellenhof,R.;Zalaudek,I.;Kittler,H.;Tschandl,P.Artificialintelligence
andsmartphoneprogramapplications(Apps):Relevancefordermatologicalpractice.Hautarzt2020,71,691–698.[CrossRef]
28. Chao,E.;Meenan,C.K.;Ferris,L.K.Smartphone-BasedApplicationsforSkinMonitoringandMelanomaDetection.Dermatol.
Clin.2017,35,551–557.[CrossRef]
29. Lucivero,F.;Jongsma,K.R.Amobilerevolutionforhealthcare?Settingtheagendaforbioethics.J.Med.Ethics2018,44,685–689.
[CrossRef]
30. Nelson,C.A.; Pérez-Chada,L.M.; Creadore,A.; Li,S.J.; Lo,K.; Manjaly,P.; Pournamdari,A.B.; Tkachenko,E.; Barbieri,J.S.;
Ko,J.M.;etal.PatientPerspectivesontheUseofArtificialIntelligenceforSkinCancerScreening:AQualitativeStudy.JAMA
Dermatol.2020,156,501–512.[CrossRef]
31. Jutzi,T.B.;Krieghoff-Henning,E.I.;Holland-Letz,T.;Utikal,J.S.;Hauschild,A.;Schadendorf,D.;Sondermann,W.;Fröhling,S.;
Hekler,A.;Schmitt,M.;etal.ArtificialIntelligenceinSkinCancerDiagnostics:ThePatients’Perspective.Front.Med.2020,7,233.
[CrossRef]
32. Petty,A.J.; Ackerson,B.; Garza,R.; Peterson,M.; Liu,B.; Green,C.; Pavlis,M.Meta-analysisofnumberneededtotreatfor
diagnosisofmelanomabyclinicalsetting.J.Am.Acad.Dermatol.2020,82,1158–1165.[CrossRef]
Cancers2022,14,3829 21of21
33. Ngoo, A.; Finnane, A.; McMeniman, E.; Tan, J.M.; Janda, M.; Soyer, H.P. Efficacy of smartphone applications in high-risk
pigmentedlesions.Australas.J.Dermatol.2018,59,e175–e182.[CrossRef][PubMed]
34. Chuchu, N.; Takwoingi, Y.; Dinnes, J.; Matin, R.N.; Bassett, O.; Moreau, J.F.; Bayliss, S.E.; Davenport, C.; Godfrey, K.;
O’Connell,S.;etal.Smartphoneapplicationsfortriagingadultswithskinlesionsthataresuspiciousformelanoma. Cochrane
DatabaseSyst.Rev.2018,12,Cd013192.[CrossRef]
35. Sun, M.D.; Kentley, J.; Mehta, P.; Dusza, S.; Halpern, A.C.; Rotemberg, V.Accuracyofcommerciallyavailablesmartphone
applicationsforthedetectionofmelanoma.Br.J.Dermatol.2021,186,744–746.[CrossRef][PubMed]
36. Maier,T.;Kulichova,D.;Schotten,K.;Astrid,R.;Ruzicka,T.;Berking,C.;Udrea,A.Accuracyofasmartphoneapplicationusing
fractalimageanalysisofpigmentedmolescomparedtoclinicaldiagnosisandhistologicalresult.J.Eur.Acad.Dermatol.Venereol.
2015,29,663–667.[CrossRef][PubMed]
37. Sangers,T.;Reeder,S.;vanderVet,S.;Jhingoer,S.;Mooyaart,A.;Siegel,D.M.;Nijsten,T.;Wakkee,M.ValidationofaMarket-
ApprovedArtificialIntelligenceMobileHealthAppforSkinCancerScreening:AProspectiveMulticenterDiagnosticAccuracy
Study.Dermatology2022,238,649–656.[CrossRef]
38. Phillips,M.;Marsden,H.;Jaffe,W.;Matin,R.N.;Wali,G.N.;Greenhalgh,J.;McGrath,E.;James,R.;Ladoyanni,E.;Bewley,A.;etal.
AssessmentofAccuracyofanArtificialIntelligenceAlgorithmtoDetectMelanomainImagesofSkinLesions.JAMANetw.Open
2019,2,e1913436.[CrossRef][PubMed]
39. EuropeanCommission.MedicalDevices:GuidanceDocument.Availableonline:https://ec.europa.eu/docsroom/documents/
10337/attachments/1/translations/en/renditions/pdf(accessedon30May2022).
40. Kessel,K.A.;Vogel,M.M.;Kessel,C.;Bier,H.;Biedermann,T.;Friess,H.;Herschbach,P.;vonEisenhart-Rothe,R.;Meyer,B.;
Kiechle,M.;etal.MobileHealthinOncology:APatientSurveyAboutApp-AssistedCancerCare.JMIRMhealthUhealth2017,
5,e81.[CrossRef]
41. Steeb,T.;Wessely,A.;Mastnik,S.;Brinker,T.J.;French,L.E.;Niesert,A.C.;Berking,C.;Heppt,M.V.PatientAttitudesandTheir
AwarenesstowardsSkinCancer-RelatedApps:Cross-SectionalSurvey.JMIRMhealthUhealth2019,7,e13844.[CrossRef]
42. Haenssle,H.A.;Fink,C.;Schneiderbauer,R.;Toberer,F.;Buhl,T.;Blum,A.;Kalloo,A.;Hassen,A.B.H.;Thomas,L.;Enk,A.;etal.
Managainstmachine: Diagnosticperformanceofadeeplearningconvolutionalneuralnetworkfordermoscopicmelanoma
recognitionincomparisonto58dermatologists.Ann.Oncol.2018,29,1836–1842.[CrossRef]
43. Polesie,S.;Gillstedt,M.;Kittler,H.;Lallas,A.;Tschandl,P.;Zalaudek,I.;Paoli,J.Attitudestowardsartificialintelligencewithin
dermatology:Aninternationalonlinesurvey.Br.J.Dermatol.2020,183,159–161.[CrossRef]
44. Haggenmüller, S.; Krieghoff-Henning, E.; Jutzi, T.; Trapp, N.; Kiehl, L.; Utikal, J.S.; Fabian, S.; Brinker, T.J.DigitalNatives’
Preferences on Mobile Artificial Intelligence Apps for Skin Cancer Diagnostics: Survey Study. JMIR Mhealth Uhealth 2021,
9,e22909.[CrossRef]
45. Janda,M.;Horsham,C.;Koh,U.;Gillespie,N.;Vagenas,D.;Loescher,L.J.;Curiel-Lewandrowski,C.;Hofmann-Wellenhof,R.;
PeterSoyer,H.Evaluatinghealthcarepractitioners’viewsonstore-and-forwardteledermoscopyservicesforthediagnosisofskin
cancer.Digit.Health2019,5,2055207619828225.[CrossRef]
